European Heart Journal · 2013 · 30 citations · 0 references
MedicineCardiologyPharmacologyCardiovascular PharmacotherapyClinical PharmacologyPharmacodynamicsCardiac PharmacotherapyEndothelial DysfunctionHeart FailureHeart Failure PharmacotherapyHemodynamic PharmacologyPulmonary HypertensionCongestive Heart Failure ManagementHeart Failure PharmacologyHeart Failure PhysiologyHemodynamic Drug EffectsLeft Ventricular Ejection Fraction DeclinePulmonary Hypertension PharmacologySoluble Guanylate Cyclase StimulatorsVascular Endothelial Dysfunction
Purpose: Approximately 50% of patients with heart failure have a preserved left ventricular ejection fraction (HFpEF). Concomitant pulmonary hypertension (PH) is a major determinant of mortality in this population and preclinical studies suggest that deficient nitric oxide-soluble guanylate cyclase (sGC)-cGMP signaling underlies impaired cardiac relaxation and endothelial dysfunction in these patients. The Phase IIa DILATE-1 study characterized the hemodynamic effects, safety, and pharmacokinetics (PK) of single doses of riociguat, a novel sGC stimulator, in patients with PH due to diastolic HF. Methods: Clinically stable patients receiving optimized diuretic and anti-hypertensive therapy were eligible for the study if they had a left ventricular ejection fraction >50%, mean pulmonary artery pressure (mPAP) ≥25 mmHg, and pulmonary capillary wedge pressure (PCWP) >15 mmHg at rest. Patients received single oral doses of placebo or riociguat (0.5, 1, or 2 mg). The primary efficacy variable was the peak decrease in mPAP from baseline up to 6 hours after a single dose of riociguat 2 mg vs. placebo. Secondary outcomes included hemodynamic and echocardiographic parameters, safety variables, and PK. Results: Of the 39 patients with chronic HFpEF randomized, 36 were valid for per protocol analysis (61% female, 44% atrial fibrillation). There was no significant change in peak decrease in mPAP in the riociguat 2 mg arm (−5.1 mmHg; n=10) vs. placebo (−6.3 mmHg; n=11; P=0.55). However, riociguat 2 mg significantly increased stroke volume (SV; baseline 75±27 mL, average placebo-corrected change over 6 hours +9 mL [95% CI 0.4 to 17 mL]; P<0.05) and decreased systolic blood pressure (SBP; baseline 142±25 mmHg, −12 mmHg [95% CI −22 to −1 mmHg]; P<0.05) and right ventricular end-diastolic (RVED) area (baseline 24±12 cm2, –5.6 cm2 [95% CI −11 to −0.3 cm2]; P<0.05) vs. placebo, without significantly changing pulmonary vascular resistance (PVR), transpulmonary pressure gradient (TPG), or heart rate (HR). Riociguat was well tolerated, and increased flow did not result in increased PCWP. Conclusions: Single doses of riociguat significantly increased SV and decreased SBP and RVED area in patients with diastolic HF and PH, without altering mPAP, PVR, TPG, PCWP, or HR. Future long-term studies will have to clarify the benefit of chronic riociguat treatment on clinical outcomes, with a focus on the effects on left ventricular relaxation and mitral regurgitation.